Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome
Uveitis secondary to chronic autoimmune disease, such as ALPS, offer long-term challenges for ocular health management. Due to the recurrent nature of uveitis flares in patients with ALPS, long-term ophthalmic and systemic management may be warranted with low-dose maintenance topical corticosteroid or systemic immunomodulation. Response to topical and systemic therapy can be highly patient specific. Complex side effect profiles of many systemic immunotherapies make drug tolerability an important treatment consideration. Multidisciplinary coordination of systemic immunosuppression should be tailored to the patient's anti-inflammatory needs, as well as careful monitoring of adverse events.
Authors
- Brent Timperley
- H. Nida Sen (ORCID: https://orcid.org/0000-0002-5919-0377)
- Helen Song (ORCID: https://orcid.org/0000-0002-6375-1894)
- Eric B. Suhler (ORCID: https://orcid.org/0000-0003-3674-037X)
- Nam V. Nguyen (ORCID: https://orcid.org/0000-0001-5396-3079)
- Steven Yeh
- Jack Begley
- M.H. Snow
- Timothy Kaftan
- Thomas Hejkal
Institutions
- Nebraska Medical Center (US)
- Emory University (US)
- Oregon Health & Science University (US)
- George Washington University (US)
- Emory Eye Center (US)
- Hematology & Oncology Consultants (US)
- Minnesota Eye Consultants (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Journal of Ophthalmic Inflammation and Infection
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1186/s12348-025-00530-5
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Edward Mallinckrodt, Jr. Foundation
- Retina Research Foundation
- National Institutes of Health